Humacyte Inc (NASDAQ: HUMA) kicked off on Monday, down -8.13% from the previous trading day, before settling in for the closing price of $1.23. Over the past 52 weeks, HUMA has traded in a range of $1.13-$6.77.
A company in the Healthcare sector has jumped its sales by 42.43% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 73.17%. With a float of $158.01 million, this company’s outstanding shares have now reached $158.84 million.
Humacyte Inc (HUMA) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Humacyte Inc is 15.62%, while institutional ownership is 24.69%. The most recent insider transaction that took place on Aug 19 ’25, was worth 1,793,000. In this transaction Director of this company sold 1,100,000 shares at a rate of $1.63, taking the stock ownership to the 591,685 shares. Before that another transaction happened on Aug 18 ’25, when Company’s Director sold 549,360 for $1.83, making the entire transaction worth $1,005,329. This insider now owns 1,691,685 shares in total.
Humacyte Inc (HUMA) Latest Financial update
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -0.21 earnings per share (EPS), higher than consensus estimate (set at -0.25) by 0.05. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.12 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 73.17% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 49.32% during the next five years compared to 42.43% growth over the previous five years of trading.
Humacyte Inc (NASDAQ: HUMA) Trading Performance Indicators
Take a look at Humacyte Inc’s (HUMA) current performance indicators. Last quarter, stock had a quick ratio of 0.90. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 134.79.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.24, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach -0.49 in one year’s time.
Technical Analysis of Humacyte Inc (HUMA)
Let’s dig in a bit further. During the last 5-days, its volume was 6.81 million. That was better than the volume of 4.34 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 10.39%.
During the past 100 days, Humacyte Inc’s (HUMA) raw stochastic average was set at 0.87%, which indicates a significant decrease from 2.26% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1154 in the past 14 days, which was lower than the 0.1543 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.6217, while its 200-day Moving Average is $2.1602. However, in the short run, Humacyte Inc’s stock first resistance to watch stands at $1.1883. Second resistance stands at $1.2467. The third major resistance level sits at $1.2833. If the price goes on to break the first support level at $1.0933, it is likely to go to the next support level at $1.0567. The third support level lies at $0.9983 if the price breaches the second support level.
Humacyte Inc (NASDAQ: HUMA) Key Stats
The company with the Market Capitalisation of 211.61 million has total of 158,372K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -148,700 K annual income. Company’s last quarter sales were recorded 300 K and last quarter income was -37,660 K.
